Hong Kong · Delayed Price · Currency is HKD CanSino Biologics Company Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China.
The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N.
meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial.
Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine.
The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
| Country | China |
| Founded | 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,105 |
| CEO | Xuefeng Yu |
Contact Details
Address: 401-420, Biomedical Park Tianjin, 300457 China | |
| Phone | 86 022 5821 3600 |
| Website | cansinotech.com |
Stock Details
| Ticker Symbol | 6185 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003F01 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Xuefeng Yu | Chief Executive Officer |
| Ming Liu | Chief Financial Officer |
| Shou-Bai Chao | Chief Operating Officer |